Table 3.

The frequency of use and the hazard ratios based on months of use of the therapy for drugs or classes with sufficient numbers for analysis in the incident diabetic dataset.

Variable	Number (%)	Unadjusted HR	Adjusted HR
Insulin
0	12261 (90.3)	Ref^	Ref^
1 to 5 months	668(4.9)	1.6 (1.2,2.2)	2.0(1.5,2.6)
6 to 11 months	268(2.0)	2.4 (1.6,3.5)	2.9(2.0, 4.2)
12 months or more	379(2.8)	2.4(1.8,3.3)	2.9(2.1,3.9)
Sulfonylureas
0	8527(62.8)	Ref^	Ref^
1 to 5 months	1929(14.2)	1.0 (0.8, 1.3)	1.0(0.8,1.2)
6 to 11 months	1047(7.7)	1.6(1.2,2.0)	1.5(1.2,2.0)
12 months or more	2073(15.3)	2.0(1.7, 2.4)	1.8(1.5,2.2)
Biguanide
0	3554(26.2)	Ref^	Ref^
1 to 5 months	3632(26.8)	0.6(0.5,0.8)	0.7(0.5, 0.8)
6 to 11 months	2454(18.1)	1.0(0.8,1.2)	1.0(0.8,1.3)
12 months or more	3936(29.0)	1.2(1.0,1.5)	1.3(1.0,1.5)
Thiazolidinediones
0	11,391 (83.9)	Ref+	Ref
1 to 5 months	950(7.0)	0.8 (0.6, 1.1)	0.9(0.7,1.2)
6 to 11 months	567(4.2)	0.6 (0.4,0.9)	0.6(0.4, 1.0)
12 months or more	668(4.9)	0.7 (0.5, 1.1)	0.7(0.4, 1.1)
Rosiglitazone
0	27780 (96.0)	Ref+	Ref
1 to 5 months	517(1.8)	0.8 (0.6,1.2)	0.9 (0.7, 1.3)
6 to 11 months	342 (1.2)	0.6 (0.4,1.0)	0.6 (0.4, 1.1)
12 months or more	288(1.0)	0.7(0.4,1.1)	0.7(0.6, 1.3)
Pioglitazone
0	13082(96.4)	Ref	Ref
1 to 5 months	204(1.5)	0.9(0.5,1.6)	0.9(0.5,1.7)
6 to 11 months	123(0.91)	0.6(0.2,1.5)	0.6 (0.2,1.7)
12 months or more	167(1.2)	0.8 (0.6,1.9)	0.8 (0.7,1.1)

^{^}Test for trend p-value <0.001

⁺p-value <0.05.